The foundation recaps the 2020 Ferring recall of intranasal desmopressin (DDAVP/Stimate) for superpotency and notes that in June 2022 the company said the nasal spray would not be available until mid-2024 at the earliest. It lists practical alternatives for patients with von Willebrand disease and mild hemophilia A: STAQ Pharma's DDAVP nasal spray (distributing since September 2021), tranexamic acid or aminocaproic acid, IV or subcutaneous DDAVP, and factor replacement for severe cases.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.